Thermo Fisher Scientific Work in process increased by 6.0% to $942.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 7.8%, from $874.00M to $942.00M. Over 5 years (FY 2020 to FY 2025), Work in process shows an upward trend with a 10.5% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase may indicate production bottlenecks or scaling efforts, while a decrease suggests efficient throughput or reduced manufacturing activity.
Represents the value of goods that have entered the production process but are not yet finished. For a manufacturer like...
Peers in medical device manufacturing typically maintain lean WIP levels to optimize cash conversion cycles.
inv_work_in_progress| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $652.00M | $680.00M | $676.00M | $723.00M | $699.00M | $677.00M | $660.00M | $708.00M | $760.00M | $743.00M | $705.00M | $787.00M | $825.00M | $902.00M | $755.00M | $874.00M | $947.00M | $990.00M | $889.00M | $942.00M |
| QoQ Change | — | +4.3% | -0.6% | +7.0% | -3.3% | -3.1% | -2.5% | +7.3% | +7.3% | -2.2% | -5.1% | +11.6% | +4.8% | +9.3% | -16.3% | +15.8% | +8.4% | +4.5% | -10.2% | +6.0% |
| YoY Change | — | — | — | — | +7.2% | -0.4% | -2.4% | -2.1% | +8.7% | +9.7% | +6.8% | +11.2% | +8.6% | +21.4% | +7.1% | +11.1% | +14.8% | +9.8% | +17.7% | +7.8% |
| % of Inventories | 14.1% | 13.9% | 13.4% | 13.2% | 12.3% | 11.8% | 11.7% | 12.5% | 13.4% | 13.7% | 13.9% | 15.3% | 15.9% | 16.6% | 15.2% | 16.7% | 17.0% | 17.2% | 16.4% | 17.1% |
| Share Change | — | -0.2pp | -0.5pp | -0.2pp | -0.9pp | -0.5pp | -0.1pp | +0.8pp | +0.9pp | +0.3pp | +0.1pp | +1.5pp | +0.5pp | +0.7pp | -1.4pp | +1.6pp | +0.3pp | +0.2pp | -0.8pp | +0.8pp |